vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and California BanCorp \ CA (BCAL). Click either name above to swap in a different company.

California BanCorp \ CA is the larger business by last-quarter revenue ($45.9M vs $44.9M, roughly 1.0× AbCellera Biologics Inc.). California BanCorp \ CA runs the higher net margin — 35.8% vs -19.9%, a 55.7% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 0.8%). California BanCorp \ CA produced more free cash flow last quarter ($56.9M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 44.7%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

ABCL vs BCAL — Head-to-Head

Bigger by revenue
BCAL
BCAL
1.0× larger
BCAL
$45.9M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+787.6% gap
ABCL
788.4%
0.8%
BCAL
Higher net margin
BCAL
BCAL
55.7% more per $
BCAL
35.8%
-19.9%
ABCL
More free cash flow
BCAL
BCAL
$101.5M more FCF
BCAL
$56.9M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
44.7%
BCAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
BCAL
BCAL
Revenue
$44.9M
$45.9M
Net Profit
$-8.9M
$16.4M
Gross Margin
Operating Margin
-63.7%
48.8%
Net Margin
-19.9%
35.8%
Revenue YoY
788.4%
0.8%
Net Profit YoY
73.9%
-2.1%
EPS (diluted)
$-0.03
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
BCAL
BCAL
Q4 25
$44.9M
$45.9M
Q3 25
$9.0M
$45.2M
Q2 25
$17.1M
$44.3M
Q1 25
$4.2M
$44.8M
Q4 24
$5.0M
$45.5M
Q3 24
$6.5M
$38.1M
Q2 24
$7.3M
$22.2M
Q1 24
$10.0M
$21.9M
Net Profit
ABCL
ABCL
BCAL
BCAL
Q4 25
$-8.9M
$16.4M
Q3 25
$-57.1M
$15.7M
Q2 25
$-34.7M
$14.1M
Q1 25
$-45.6M
$16.9M
Q4 24
$16.8M
Q3 24
$-51.1M
$-16.5M
Q2 24
$-36.9M
$190.0K
Q1 24
$-40.6M
$4.9M
Operating Margin
ABCL
ABCL
BCAL
BCAL
Q4 25
-63.7%
48.8%
Q3 25
-851.8%
48.3%
Q2 25
-290.2%
45.3%
Q1 25
-1479.6%
52.8%
Q4 24
52.2%
Q3 24
-1439.4%
-59.1%
Q2 24
-1276.2%
1.3%
Q1 24
-551.5%
33.1%
Net Margin
ABCL
ABCL
BCAL
BCAL
Q4 25
-19.9%
35.8%
Q3 25
-637.8%
34.7%
Q2 25
-203.3%
31.8%
Q1 25
-1077.2%
37.6%
Q4 24
37.7%
Q3 24
-785.4%
-43.2%
Q2 24
-504.3%
0.9%
Q1 24
-408.0%
22.5%
EPS (diluted)
ABCL
ABCL
BCAL
BCAL
Q4 25
$-0.03
$0.50
Q3 25
$-0.19
$0.48
Q2 25
$-0.12
$0.43
Q1 25
$-0.15
$0.52
Q4 24
$0.54
Q3 24
$-0.17
$-0.59
Q2 24
$-0.13
$0.01
Q1 24
$-0.14
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
BCAL
BCAL
Cash + ST InvestmentsLiquidity on hand
$128.5M
$399.9M
Total DebtLower is stronger
$33.8M
Stockholders' EquityBook value
$966.9M
$576.6M
Total Assets
$1.4B
$4.0B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
BCAL
BCAL
Q4 25
$128.5M
$399.9M
Q3 25
$83.2M
$559.2M
Q2 25
$92.4M
$430.1M
Q1 25
$159.3M
$439.2M
Q4 24
$156.3M
$388.2M
Q3 24
$126.6M
$614.4M
Q2 24
$148.3M
$104.7M
Q1 24
$123.6M
$86.5M
Total Debt
ABCL
ABCL
BCAL
BCAL
Q4 25
$33.8M
Q3 25
$33.4M
Q2 25
$52.9M
Q1 25
$70.3M
Q4 24
$69.7M
Q3 24
$69.1M
Q2 24
$42.9M
Q1 24
$44.9M
Stockholders' Equity
ABCL
ABCL
BCAL
BCAL
Q4 25
$966.9M
$576.6M
Q3 25
$964.0M
$564.7M
Q2 25
$1.0B
$547.6M
Q1 25
$1.0B
$531.4M
Q4 24
$1.1B
$511.8M
Q3 24
$1.1B
$498.1M
Q2 24
$1.1B
$293.2M
Q1 24
$1.1B
$292.5M
Total Assets
ABCL
ABCL
BCAL
BCAL
Q4 25
$1.4B
$4.0B
Q3 25
$1.4B
$4.1B
Q2 25
$1.4B
$4.0B
Q1 25
$1.3B
$4.0B
Q4 24
$1.4B
$4.0B
Q3 24
$1.4B
$4.4B
Q2 24
$1.4B
$2.3B
Q1 24
$1.5B
$2.3B
Debt / Equity
ABCL
ABCL
BCAL
BCAL
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
BCAL
BCAL
Operating Cash FlowLast quarter
$-34.7M
$57.3M
Free Cash FlowOCF − Capex
$-44.6M
$56.9M
FCF MarginFCF / Revenue
-99.4%
124.1%
Capex IntensityCapex / Revenue
21.9%
0.8%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
BCAL
BCAL
Q4 25
$-34.7M
$57.3M
Q3 25
$-52.6M
$16.0M
Q2 25
$-32.4M
$13.4M
Q1 25
$-11.6M
$7.0M
Q4 24
$-108.6M
$50.3M
Q3 24
$-28.9M
$18.3M
Q2 24
$-30.0M
$309.0K
Q1 24
$-41.7M
$8.1M
Free Cash Flow
ABCL
ABCL
BCAL
BCAL
Q4 25
$-44.6M
$56.9M
Q3 25
$-61.5M
$15.9M
Q2 25
$-45.8M
$13.4M
Q1 25
$-22.2M
$6.9M
Q4 24
$-187.0M
$49.7M
Q3 24
$-47.4M
$18.1M
Q2 24
$-50.1M
$171.0K
Q1 24
$-65.8M
$8.0M
FCF Margin
ABCL
ABCL
BCAL
BCAL
Q4 25
-99.4%
124.1%
Q3 25
-687.0%
35.1%
Q2 25
-267.9%
30.2%
Q1 25
-524.0%
15.3%
Q4 24
-3702.8%
109.2%
Q3 24
-728.4%
47.5%
Q2 24
-683.8%
0.8%
Q1 24
-661.5%
36.4%
Capex Intensity
ABCL
ABCL
BCAL
BCAL
Q4 25
21.9%
0.8%
Q3 25
99.7%
0.2%
Q2 25
78.2%
0.1%
Q1 25
251.1%
0.2%
Q4 24
1552.7%
1.2%
Q3 24
284.6%
0.5%
Q2 24
274.6%
0.6%
Q1 24
242.5%
0.4%
Cash Conversion
ABCL
ABCL
BCAL
BCAL
Q4 25
3.49×
Q3 25
1.02×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons